0001454189-12-000002.txt : 20120731 0001454189-12-000002.hdr.sgml : 20120731 20120731170433 ACCESSION NUMBER: 0001454189-12-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506 FILED AS OF DATE: 20120731 DATE AS OF CHANGE: 20120731 EFFECTIVENESS DATE: 20120731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Auspex Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001454189 IRS NUMBER: 954862842 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-182048 FILM NUMBER: 12997549 BUSINESS ADDRESS: STREET 1: 3366 N. TORREY PINES COURT STREET 2: SUITE 225 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 558-2400 MAIL ADDRESS: STREET 1: 3366 N. TORREY PINES COURT STREET 2: SUITE 225 CITY: LA JOLLA STATE: CA ZIP: 92037 D 1 primary_doc.xml X0706 D LIVE 0001454189 Auspex Pharmaceuticals, Inc. 3366 N. TORREY PINES COURT SUITE 225 LA JOLLA CA CALIFORNIA 92037 (858) 558-2400 DELAWARE None None Corporation true 2007 Lawrence C. Fritz c/o Auspex Pharmaceuticals, Inc. 3366 N. Torrey Pines Court, Suite 225 La Jolla CA CALIFORNIA 92037 Executive Officer Director David Collier c/o CMEA Ventures 1 Letterman Dr., Building C, Ste. CM500 San Francisco CA CALIFORNIA 94129 Director Sep Sharshar c/o Auspex Pharmaceuticals, Inc. 3366 N. Torrey Pines Court, Suite 225 La Jolla CA CALIFORNIA 92037 Director Samuel Saks c/o Auspex Pharmaceuticals, Inc. 3366 N. Torrey Pines Court, Suite 225 La Jolla CA CALIFORNIA 92037 Director Andreas Sommer c/o Auspex Pharmaceuticals, Inc. 3366 N. Torrey Pines Court, Suite 225 La Jolla CA CALIFORNIA 92037 Executive Officer David Stamler c/o Auspex Pharmaceuticals, Inc. 3366 N. Torrey Pines Court, Suite 225 La Jolla CA CALIFORNIA 92037 Executive Officer Pratik Shah c/o Auspex Pharmaceuticals, Inc. 3366 N. Torrey Pines Court, Suite 225 La Jolla CA CALIFORNIA 92037 Director Pharmaceuticals Decline to Disclose 06 false 2012-07-18 false true true true Promissory Notes convertible into Preferred Stock and Warrants to purchase shares of Preferred Stock were issued in connection with the Offering false 0 3000000 1500000 1500000 Warrants for the purchase of Preferred Stock were issued in connection with the Offering for no additional consideration. The aggregate number of warrant shares is contingent on a formula set forth in each of the warrants. false 5 0 0 0 false Auspex Pharmaceuticals, Inc. /s/ Lawrence C. Fritz Lawrence C. Fritz President & CEO 2012-07-31